

	1 Month	3 Month	YTD	1 Year	3 Year	5 Year	Inception
BIVIX (as of 4/30/25)	-5.30	-0.35	-1.96	-4.89	4.28	24.64	17.42
S&P 1500 TR Index	-0.85	-7.92	-5.30	11.12	11.58	15.39	12.42
Morningstar Cat. Avg.	-1.27	-4.68	-2.03	4.85	5.48	7.40	4.81
BIVIX (as of 3/31/25)	3.29	3.52	3.52	0.93	8.58	28.21	18.44

Performance data guoted represents past performance; past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance of the fund may be lower or higher than the performance quoted. To obtain performance data current to the most recent month-end, please call 1-855-466-3406. *"Morningstar Cat. Avg." is the Morningstar Long/Short Equity category average.

Returns over one year are annualized and include the reinvestment of dividends and income. The fund imposes a 1.00% redemption fee on shares sold within 60 days. All data presented above is as of 4/30/25, unless otherwise indicated. Fund inception: 6/19/17. Total operating fund expenses as of 3/1/25 for Class I shares: 3.17% (gross expense ratio), 2.23% (expense cap). See page 3 for additional information.

MONTHLY FUND REVIEW

The Invenomic Fund returned -5.30% compared to -0.85% for the S&P 1500 Index and -1.27% for the Morningstar Long/Short Equity category average. The long portfolio detracted 3.12% and the short portfolio detracted 2.46% during the month, on a gross basis. The portfolio averaged 112.3% long and -89.4% short, resulting in average net exposure of 22.9% and average gross exposure of 201.8%. The portfolio has 178 long and 90 short positions as of month-end.

MONTHLY COMMENTARY

Market volatility in April was extreme, largely due to the dramatic shifts in global trade policy coming out of the White House. Equity markets dropped over 10% early in the month only to recover most of the loss by month-end. The uncertainty around the impact of the tariffs caused investors to follow the old playbook of leaning into momentum. The Bloomberg US Pure

Momentum Index was up 2.15%, the strongest month since February 2024. Momentum began to rally sharply on March 10th and was up 4.85% by the end of April. This strong upward move is notable because the index has historically averaged less than 1% a year.

Momentum Right Tail's Crowding, S&P 500 6-Feb-25 Recession ----Latest 6-Dec -24 40.0 COVID GFC TMT Bubble 13-Apr-99 30-Jan-06 30.0 Jan-08 13-Oct-93 20.0 Oil Pri 10-Mar-25 10.0 86.3%ile 0.0 -10.0 25-Jan-22 Currently at 98.3%ile 17-Sep-09 as of 09May-25 -20.0 '06 '08 '10 '12 '14 '16 '18 '20 90 '92 '94 '96 '98 '00 '02 '04 '22 '24

Source: J.P. Morgan Equity Strategy & Quantitative Research.

Economic conditions remain highly uncertain. There is no assurance these opinions or forecasts will come to p29250521-4522607


MOMENTUM CROWDING

INVENOMIC FUND (BIVIX) APRIL 2025 COMMENTARY



We believe that we are in the blowoff phase of this momentum rally that started on February 2, 2023. During this period, beginning approximately two years and two months ago, the Bloomberg US Pure Momentum Index is up 17.68%. For context, the total return for the Pure Momentum Index since the inception of the fund is just 11.42%. We expect a sharp reversal in the momentum factor at some point in the foreseeable future as investors rotate capital from expensive to cheap companies. We often get asked what the catalyst will be but unfortunately that is something impossible to know. What we do know is that the crowding in the momentum factor is near all-time highs as seen in the chart on the previous page. Elevated levels of momentum crowding like we are currently seeing have historically had sharp corrections.

Looking at the portfolio today, we have rarely seen such a wide discrepancy between the valuation of our longs and shorts. As of month-end, our long portfolio had a P/E Ratio of 8.9x and the short portfolio had a P/E of 42.6x. We believe this is one of the most attractively valued long portfolios we have had in the history of the fund.




Source: Bloomberg, Morningstar Direct, Invenomic.

These discrepancies extend to the market cap spectrum as well. Looking at market cap performance over the trailing twelve months (TTM) through the end of April, large-caps have performed meaningfully better than the rest of the market. This remains consistent when we look at longer time periods as well. During the last decade, the companies with the largest market caps have comfortably been the best performers. As of the end of April, the forward one-year P/E ratio for the S&P 500 is 21.2x compared to 15.9x for the S&P 400 Mid-Cap Index and 15.2x for the S&P 600 Small-Cap Index.

We generally have a tilt towards smaller market capitalizations in our portfolio. While we are comfortable going long smaller market caps, we are very careful about shorting companies with market capitalizations below \$2 billion from a risk management perspective. In the current environment, our short portfolio is more concentrated in large-caps than almost any other time in our history. On the long side we continue to find new compelling opportunities in mid and small-caps, while opportunities in large-caps are increasingly becoming harder to come by.





Source: Invenomic.

We couldn't be more excited about the current opportunities in the portfolio. We anticipate a rewarding outcome over the long run coupled with heightened volatility over the short run. Rarely have we seen a market as stretched as it is today. Historically, these sorts of divergences have corrected themselves through meaningful capital rotation from winners into laggards. We feel that the portfolio is well set up to benefit from such a rotation.

Please do not hesitate to reach out if you have any questions.

INVENOMIC FUND (BIVIX) APRIL 2025 COMMENTARY



Investors should carefully consider the investment objectives, risks, charges, and expenses of the Invenomic Fund. This and other important information about the Invenomic Fund is contained in the prospectus, which can be obtained at invenomic.com or by calling 1-855-466-3406. The prospectus should be read carefully before investing.

The Invenomic Fund is distributed by Northern Lights Distributors LLC, member FINRA/SIPC. Invenomic Capital Management is not affiliated with Northern Lights Distributors, LLC. To obtain performance as of the latest month-end, please call 1-855-466-3406.

Economic conditions remain highly uncertain. There is no assurance these opinions or forecasts will come to pass.

<u>Important Risk Information</u>: Mutual fund investing involves risk. Principal loss is possible. The Fund may use derivatives, including options, which may not perform as anticipated by the Adviser, may not be able to be closed out at a favorable time or price, or may increase the Fund's volatility. A counterparty's inability to fulfill its obligation may result in financial loss to the Fund. Increases and decreases in the value of the Fund's portfolio may be magnified when the Fund uses leverage.

The fund may make short sales of securities, which involves the risk that losses may exceed the original amount invested. Investments in debt securities typically decrease when interest rates rise. This risk is usually greater for longer-term debt securities. Investments in lower rated and non-rated securities present a greater risk of loss to principal and interest than higher-rated securities. Investing in foreign securities exposes investors to economic, political and market risks, and fluctuations in foreign currencies. The fund may invest in the securities of small and medium sized companies. Small and medium company investing subjects investors to additional risks, including security price volatility and less liquidity than investing in larger companies.

Fund expenses listed are as of 3/1/2025. Pursuant to the agreement, the Adviser has agreed to waive its fees and/or absorb expenses of the Fund to ensure that Total Annual Fund Operating Expenses (excluding any front-end or contingent deferred sales loads, brokerage fees and commissions, acquired fund fees and expenses, borrowing costs (such as interest and dividend expense on securities sold short), taxes and extraordinary or non-recurring expenses, including, but not limited to, litigation) for the Fund do not exceed 2.23%, 2.48% and 1.98% of the Fund's average net assets, for Institutional Class, Investor Class and Super Institutional Class shares, respectively, through February 28, 2026. The Adviser is permitted to receive reimbursement from the Fund for fees it waived and Fund expenses it paid, subject to the limitation that: (1) the reimbursement for fees and expenses will be made only if payable within three years from the date the fees and expenses were initially waived or reimbursed; and (2) the reimbursement may not be made if it would cause the expense limitation in effect at the time of the waiver or currently in effect, whichever is lower, to be exceeded. This operating expense limitation agreement can be terminated only by, or with the consent of, the Board of Trustees.

The indices shown are for informational purposes only, are not reflective of any investment, nor are they professionally managed. As it is not possible to invest in the indices, the data shown does not reflect or compare features of an actual investment, such as its objectives costs and expenses, liquidity, safety, guarantees or insurance fluctuation of principal or return, or tax features. There is no guarantee that any investment strategy will achieve its objectives, generate profits, or avoid losses.

The investment objective of the Invenomic Fund is to seek long term capital appreciation.

INVENOMIC FUND (BIVIX) APRIL 2025 COMMENTARY



The S&P 1500 combines three leading indices, the S&P 500, the S&P MidCap 400, and the S&P SmallCap 600, to cover approximately 90% of U.S. market capitalization. The Morningstar Long-Short Equity Category is an average monthly return of all funds in the Morningstar Long-Short Equity Category, including the Fund. The category contains a universe of funds with similar investment objectives and investment style, as defined by Morningstar. The S&P 500 Index is a market-capitalizationweighted index of 500 leading publicly traded companies in the U.S. Mega cap is a designation for the largest companies in the investment universe as measured by market capitalization. While the exact thresholds change with market conditions, mega cap generally refers to companies with a market capitalization above \$200 billion. The Nasdaq Composite Index is a market capitalization-weighted index of more than 3,700 stocks listed on the Nasdaq stock exchange. The Russell 2000 Index is a subset of the Russell 3000® Index representing approximately 10% of the total market capitalization of that index. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership. The Russell 1000 Value/Growth Index measures the relative performance of a combination of their component indexes, the Russell 1000 Value Index and the Russell 1000 Growth Index and a cash component. The Russell 1000 Value/Growth Index represents a positive weighting on the Russell 1000 Value Index and a negative weighting on the Russell 1000 Growth Index. PMOMENUS (Bloomberg Pure US Momentum Portfolio) represents the return of Momentum factor from PORT <GO> US Equity model in Bloomberg. This factor separates stocks based on their 1-year price performance. Long exposure is the percentage of dollar capital invested in the long book. Short exposure is the percentage of dollar capital in the short book. Net exposure is the long exposure minus short exposure. Gross exposure is the long exposure plus short exposure. The forward price-to-sales (P/S) ratio is calculated by dividing the current stock price by the expected sales per share for the next period. Performance of the indices and Morningstar Category Average is generated on the 1st business day of the month.

This commentary contains forward looking statements that are meant to represent the economy as of the date this is written and not intended to represent the fund. Due to uncertainties and risks associated with the markets in general, the views expressed here may not occur and are subject to change at any time.